TMCnet News

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors
[November 19, 2020]

The Law Offices of Frank R. Cruz Announces Investigation of Supernus Pharmaceuticals, Inc. (SUPN) on Behalf of Investors


The Law Offices of Frank R. Cruz announces an investigation of Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") (NASDAQ: SUPN) on behalf of investors concerning the Company's possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On November 9, 2020, after the market cosed, Supernus disclosed receipt of a complete response letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding its new drug application ("NDA") for SPN-812 for the treatment of ADHD in pediatric patients aged 6-17 years old. According to the CRL, the NDA "is not ready for approval in its present form." Among other things, "[t]he primary issue cited in the SPN-812 CRL relates to the Company's in-house laboratory that conducts analytical testing, which recently moved to a new location."



On this news, Supernus's stock price fell $3.88 per share, or approximately 16%, to close at $21.08 per share on November 10, 2020, thereby injuring investors.

Follow us for updates on Twitter (News - Alert): twitter.com/FRC_LAW.


If you purchased Supernus securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


[ Back To TMCnet.com's Homepage ]